Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

August 2025

Put It on the Board

August 2025—In a position statement released in July, the CAP urged policymakers to consider scientific and logistical evidence and to protect the integrity and safety of the national blood supply. The statement was issued in response to legislation proposed in several states that would require blood product labeling based on donor vaccination status or mandate hospitals and blood collectors to honor requests for directed and autologous donations. Misinformation surrounding COVID-19 and mRNA vaccines has led to a growing number of patient requests for blood transfusions exclusively from unvaccinated donors.

Systemic Mastocytosis: Overview of Disease and Diagnosis for Pathologists

Webinar presenter Sheeja Pullarkat, MD, on behalf of Blueprint Medicines, Professor of Pathology and Laboratory Medicine, Director of Hematopathology Fellowship Program, Hematopathology and Hematology, UCLA Health, discusses Systemic Mastocytosis (SM), SM evaluation and diagnostic work-up, and technical challenges and best practices for optimizing testing. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast June 2, 2022.

Community-based rapid NGS offers considerable advantages in clinical cancer care

Webinar presenter Brandon Sheffield, MD, Anatomic and Molecular Pathologist, Department of Laboratory Medicine, William Osler Health System, discusses William Osler Health System’s experience with implementing next-generation sequencing (NGS) in routine oncology biomarker testing. In their pilot study, 578 pan-cancer solid tumor samples underwent genomic profiling. All testing was performed by one group of technologists within the same division of the laboratory, achieving a median turnaround time (TAT) of 3 business days. Dr. Sheffield will elaborate on the importance of timely availability of biomarker results for optimal cancer care, demostrate the feasibility of such TATs in community-based hospitals using fast and automated NGS, and describe the novel approach of integrating NGS with routine immunohistochemistry. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast August 3, 2022.

Methylation Analysis: A new approach to sarcoma classification

Webinar presenters Andreas von Deimling, MD, Department of Neuropathology, Institute of Pathology, University Heidelberg, and Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and Christian Kölsche, MD, Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, discuss sarcoma classification by DNA methylation profiling, principles of methylation-based tumor classification, approaches to sarcomas with methylation analysis, and practical examples and outlook of accessing the tool. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast July 20, 2022.